Category Archives: Regenerative Medicine

Around 800 BHF runners took to the streets of the British capitalfor the iconic 2022 TCS London Marathon on Sunday 2nd October.

As the 2022 Charity of the Year, our runners have raised nearly 2 million so far, with further donations expected. This will help fund lifesaving science into regenerative medicine, a cutting-edge field of research that has the power to unlock a cure for heart failure.

Among ourmarathon runners was Professor Sanjay Sinha from the University of Cambridge, who completed the event in around four hours fifty minutes.

Professor Sanjay is leading ground-breaking research behind the Heart Healing Patch. Made of stem cells, the patch could be applied to the heart to help repair damage caused by a heart attack and could help save and improve the lives of millions worldwide affected by heart failure.

Nearly a million people in the UK are currently living with heart failure. Poignantly, Sanjays running number for the marathon was 17,000 which is how many people are diagnosed with heart failure in the UK each month.

After crossing the finish line Professor Sanjay Sinha, our Senior Clinical Research Fellow at the University of Cambridge, said: Taking part in the 2022 TCS London Marathon for the British Heart Foundation (BHF), was such a huge challenge. It was my first marathon and an absolutely incredible experience. The atmosphere on the day was electric and I wouldnt have made it round the last few miles without the support from the crowds, who were amazing.

"I am proud to know that by doing this, together with over 800 other BHF runners, weve helped the BHF to continue to fund pioneering research into regenerative medicine including the development of our Heart Healing Patch, which could save and improve the lives of millions of people worldwide affected by heart failure.

The money raised by the BHFs runners and supporters at this years event could be truly transformative and help us carry out the first clinical trials of the patch in patients. I want to thank every single person who has already donated.

Our Chief Executive Dr Charmaine Griffiths said: It was a truly heart-warming and inspirational day cheering on all our Team BHF runners, made even more special with the BHF being the 2022 TCS London Marathons charity of the year.

The hundreds of runners who took part in the iconic TCS London Marathon 2022 have helped us to turbo charge our pioneering research into regenerative medicine, which includes the development of a Heart Healing Patch, which could save and improve the lives of millions of people worldwide affected by heart failure.

From all those who fundraised, donated, volunteered and supported Team BHF on the day, you have played your part in helping to get our ground-breaking research over the finish line even faster and we cannot thank you enough.

Applications for the 2023TCS London Marathon are now open.

Help to make the Heart Healing Patch a reality

See the original post:
Hundreds run for regenerative medicine research at the 2022 TCS London Marathon - British Heart Foundation

Study of Therapeutic to Restore Hearing Aims to Show Speech Perception Improvements in Individuals with Noise-Induced or Permanent Sudden Sensorineural Hearing Loss

Company Aligned with FDA on Speech Perception Primary Endpoint

Readout Expected in Q1 2023

LEXINGTON, Mass., October 12, 2022--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate potential to restore function, today announced that it has completed enrollment of its placebo-controlled Phase 2b study of FX-322 in adults with acquired sensorineural hearing loss (SNHL). The FX-322-208 study, which enrolled 142 individuals, is designed to show improvement in a pre-specified measure of speech perception. The Company plans to release study data in the first quarter of 2023.

"I am very pleased with our teams execution of this study for the first potential treatment to restore hearing for those with SNHL. The 208 study was rigorously designed to ensure the stability of an individuals hearing prior to entering the trial and to exclusively enroll those with the types hearing loss where we observed the strongest hearing improvement in prior FX-322 studies. FX-322 continues to have a favorable safety profile and we are aligned with FDA on the primary speech perception endpoint. With a successful outcome of this single-dose study, our intent is to advance the program into Phase 3 trials," said David L. Lucchino, Frequencys chief executive officer.

Mr. Lucchino continued: "We are grateful to all the study volunteers, clinicians and site staff for their time and commitment to this trial. We believe the high level of interest from patients and healthcare providers in this study further demonstrates the need for a novel, disease modifying hearing loss treatment to expand the standard of care for the millions of individuals with sensorineural hearing loss."

Story continues

FX-322-208 Study Design

FX-322-208 is a prospective, randomized, double-blinded, placebo-controlled, multi-center Phase 2b study designed to evaluate the efficacy of a single administration of FX-322 on speech perception in subjects aged 18-65 with hearing loss associated with either noise-induced or permanent idiopathic sudden SNHL. The study enrolled 142 participants, exceeding the original enrollment target of approximately 124, and is being conducted at 28 clinical sites across the US.

The Company previously aligned with the US Food and Drug Administration (FDA) on the use of the specific speech perception primary endpoint. With improved speech perception, individuals may hear words more clearly, a critical unmet need for individuals with hearing loss. The FX-322-208 study is powered at 80% (significance level of 0.05) to observe a statistically significant and clinically meaningful improvement in speech perception at day 90 following dosing, with study responders defined as individuals exceeding the upper 95% confidence interval in the speech perception test. The Company has not publicly disclosed the specific test used for the primary endpoint to maximize the rigor of the study and mitigate potential bias.

During the study, subjects participate in a range of audiologic exams, including pure-tone audiometry, word recognition in quiet, word recognition in noise, the Tinnitus Functional Index (TFI), as well as multiple patient-reported outcome measures including Frequencys proprietary patient reported outcome instrument (RADIAL) in acquired SNHL. All subjects are required to have a documented audiogram from at least six months prior to screening and most patients are evaluated over a 270-day period following dosing. The studys rigorous design includes a lead-in phase with multiple baseline measures. Subjects with instability of baseline tests are disqualified from participation in the study. Study audiometry testing sessions are recorded and monitored by third party audiologists to ensure consistency and identify any anomalies related to how tests were conducted.

In prior studies, the Company observed the greatest concentration of speech perception improvements in individuals with permanent sudden or noise-induced sensorineural hearing loss in the moderate to lower severe hearing loss range. These learnings informed the design and inclusion criteria for the FX-322-208 study. More than 200 individuals have been dosed with a single injection of FX-322 in prior or ongoing studies, and the drug candidate has continued to exhibit a favorable safety profile with no drug-related serious adverse events.

About Sensorineural Hearing Loss

Sensorineural hearing loss is the most common form of hearing loss, typically resulting from damage to sensory hair cells in the cochlea. These cells convert sound waves to signals sent to the brain which are interpreted as speech and sound. Sensory hair cells are lost due to chronic noise exposure, aging, certain viral infections or exposure to drugs that are toxic to the ear. This type of hearing loss impacts around 40 million individuals in the U.S. alone.

About Frequency Therapeutics

Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore human function first in hearing loss and then in multiple sclerosis by developing therapeutics that activate a persons innate regenerative potential within the body through the activation of progenitor cells. Frequencys hearing research focuses on cochlear restoration and auditory repair, and its lead asset, FX-322, is a small-molecule combination product candidate that is the first to show statistically significant and clinically meaningful hearing improvements in clinical trials for sensorineural hearing loss. Frequency is also following early restorative signals in MS to develop medicines with the same underlying regenerative science being brought to hearing loss.

Headquartered in Lexington, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, and the Scripps Research Institute.

For more information, visit http://www.frequencytx.com and follow Frequency on Twitter @Frequencytx.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the timing and design of the Phase 2b study (FX-322-208), including the timing of results and the ability of design features to reduce bias, the commencement of any future FX-322 trials, the interpretation and implications of the results and learnings of other FX-322 clinical studies, the treatment potential of FX-322, estimates of the size of the hearing loss population, the acceptance by the FDA of particular endpoints in the Companys trials, and the potential application of the progenitor cell activation (PCA) platform to other diseases.

These forward-looking statements are based on managements current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of COVID-19 on the Companys ongoing and planned clinical trials, research and development and manufacturing activities, the Companys business and financial markets; the Company has incurred and will continue to incur significant losses and is not and may never be profitable; the Companys need for additional funding to complete development and commercialization of any product candidate; the Companys dependence on the development of FX-322; the unproven approach of the PCA platform and the inability to identify additional potential product candidates; the lengthy, expensive and uncertain process of clinical drug development and regulatory approval; the Companys limited experience successfully obtaining marketing approval for and commercializing product candidates; the results of earlier clinical trials not being indicative of the results from later clinical trials; differences between preliminary or interim data and final data; adverse events or undesirable side effects; disruptions at the FDA and other regulatory agencies; failure to identify additional product candidates; new or changed legislation; failure to maintain Fast Track designation for FX-322 and such designation failing to result in faster development or regulatory review or approval; ability to seek and receive Breakthrough Therapy designation for FX-322; the Companys ability to enroll and retain patients in clinical trials; costly and damaging litigation, including related to product liability or intellectual property or brought by stockholders; dependence on Astellas Pharma Inc. for the development and commercialization of FX-322 outside of the United States; misconduct by employees or independent contractors; reliance on third parties, including to conduct clinical trials and manufacture product candidates; compliance with changing laws and regulations, including healthcare and environmental, health, data privacy and safety laws and regulations; failure to obtain, maintain and enforce protection of patents and other intellectual property rights covering product candidates; security breaches or failure to protect private personal information; attracting and retaining key personnel; and the Companys ability to manage growth.

These and other important factors discussed under the caption "Risk factors" in the Companys Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 9, 2022 and its other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Companys views as of any date subsequent to the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221012005144/en/

Contacts

Investor:Carlo Tanzi, Ph.D.Kendall Investor Relationsctanzi@kendallir.com 617-914-0008

Media:Frequency TherapeuticsEmail: media@frequencytx.com

See original here:
Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss - Yahoo Finance

EDEN PRAIRIE, MN, Oct. 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire SANUWAVE Health, Inc. (OTCPK: SNWV), a leading provider of next-generation wound care products, is excited to announce that three abstracts highlighting the role of the companys dermaPACE system in clinical cases were accepted to the Poster Presentation Hall at the upcoming 2022 Fall Symposium on Advanced Wound Care (SAWC) hosted by HMP Global. The conference is one of wound cares most esteemed events and will take place at Caesars Palace, Las Vegas, Nevada from October 13-16, 2022.

The following clinical cases, which examine the use of dermaPACE in patients with chronic, complex, and challenging wounds, will be presented.

1.) The Use of Non-Invasive Extracorporeal Shockwave Therapy (ESWT) Pulsed Acoustic Cellular Expression (PACE) System In Complex Wounds Related To Erythromelalgia, A Rare Skin Condition.

Dr. Marcelo de Oliveira e Silva, HOSPITAL CAXIAS DOR RIO DE JANEIRO general and plastic surgeon, UNIFESP Medical School Professor, Pontifical Catholic University (PUC) Carlos Chagas Medical Graduate Institute, coordinator, Quinta D'Or Hospital, specialist, evaluator, Brazilian Society of Plastic Surgery (SBCP), preceptor, Ivo Pitanguy Institute.

Dr. Paulo Roberto Castelleti Liborio Da Costa Brazilian Society of Plastic Surgery and Ivo Pitanguy Institute. Practices at Salgado Filho Municipal Hospital (Trauma Surgery,General Surgery) and Duque de Caxias DOr Hospital as Plastic Surgeon

2.) Extracorporeal Shockwave Therapy (ESWT) PACE-Technology: Pilot Trial to Treat Mixed Etiologies Lower Leg Ulcer in a Mobile Setting; When All Else Failed

John David Thomas, MD, FAPWCA Medical Director Solutions Medical Group, PLLC, Houston, TX. DIRECTOR OF WOUND CARE: Signature Home Health Baytown, TX; The Heights of North Houston Spring, TX; Park Manor, The Woodlands The Woodlands, TX; IPR Healthcare Systems Houston, TX; Crimson Heights Humble, TX. SPEAKER: Kerecis Omega3 Fish Skin technology. FORMER-SPEAKER: Acelity / KCI San Antonio, TX; Tissue Regenix Woundcare Inc. San Antonio, TX

3.) Extracorporeal Shockwave Therapy (ESWT) Pace-Technology: A New Approach to an Old Nemesis-Pyoderma Gangrenosum

Dr Perry Mayer; Medical Director of The Mayer Institute (TMI), Center of Excellence Hamilton Ontario Canada

Representatives from SANUWAVE will be available at SAWC booth #619 in the exhibit hall for inquiries on their ENERGY FIRST product portfolio which includes both dermaPACE and UltraMIST. The companys CEO, Kevin Richardson, and CRO, Jack Schlechtweg, will also be in attendance.

If you are attending the event and would like to schedule some time to meet with a team member, please email the companys Marketing contact Sabrina Ruelle at Sabrina.Ruelle@Sanuwave.com so she can help facilitate a meet time.

Additional information regarding SANWUAVEs product portfolio is available through their website at https://sanuwave.com/

About SANUWAVE

SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

SANUWAVEs end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the bodys normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Companys ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Companys product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Companys ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Companys periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

INVESTOR RELATIONS CONTACT:Investorrelations@Sanuwave.com

2022 GlobeNewswire, Inc., source Press Releases

See original here:
SANUWAVE's Energy First Technology to be Featured in 3 Clinical Posters at Upcoming 2022 Fall Symposium on Advanced Wound Care (SAWC) -...

WASHINGTON, Oct. 09, 2022 (GLOBE NEWSWIRE) -- Global 3D bioprinting market was valued at USD 1.5 Billion in 2021 and is projected to attain a value of USD 3.7 Billion by 2028 during the forecast period, 20222028.

Get Sample Copy of This Report: https://www.vantagemarketresearch.com/3d-bioprinting-market-1235/request-sample

As the demand for bioprinting continues to increase, so too does the need for 3D bioprinting. 3D bioprinting market uses small droplets of cell-containing material to create 3D objects in vitro It is useful for creating organs, tissues, and other structures from stem cells or other cells. It is also useful for creating customized implants and drugs.

The growing demand for 3D bioprinting has led to the development of new technologies and processes that make it easier and faster to create 3D objects. As the technology opens up new opportunities for the development of novel medical treatments, 3D bioprinting market growth is being driven by the increasing demand for personalized medicine, as well as the increasing need for customized structures and therapies. With each passing year, the technology is also becoming more affordable and accessible, making it an attractive option for clinical applications. This growth in demand will likely continue to accelerate in the future, as further advances in technology are made.

Top Players in Global 3D Bioprinting Market

Bioprinting is booming as a technology for creating tissue and organ replacement parts. The following are three factors driving demand for this innovative technology:

1. Growing aging population: The worlds population is growing older, which means there will be an increasing need for tissue and organ replacements. Bioprinting can help to fill this need by creating replacement tissues and organs from patient-specific cells. Over 1 billion people are above 60 years old and the number is projected to expand to 1.4 billion by 2050.

2. Declining supplies of natural organs and tissues: The availability of natural organs and tissues for transplantation is dwindling in worldwide 3D bioprinting market due to the increasing incidence of diseases such as Alzheimers, heart failure, and cancer. By using bioprinting, hospitals can create replacement tissues or organs specifically tailored to the needs of individual patients.

3. Progress in regenerative medicine: Regenerative medicine utilizes techniques such as cell therapy and 3D printing to restore function to damaged or diseased tissue. By printing tissue components in a controlled environment, regenerative medicine providers are able to engineers complex tissue constructs that would otherwise be extremely difficult or impossible to achieve.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.vantagemarketresearch.com/buy-now/3d-bioprinting-market-1235/0

Key Findings:

Scope of the Report:

Increasing Adoption of 3D Bioprinting for Engineering Organs

3D bioprinting market is becoming an increasingly important as it enables the rapid, low-cost fabrication of complex components and structures from a variety of biocompatible materials. Vantage Market Research estimates that global spending on 3D printing services will top $2.3 billion by 2025, with growth rates well above the average for all software categories over the same period.

3D bioprinting market currently has niche applications in large-scale industrial production, but its potential to create low-cost human tissues and organs has drawn considerable interest. This is due in part to the high degree of customization that is possible with 3D bioprinting, which can enable precise control over tissue properties, including shape, size, and composition.

Every year, more than 10,000 Americans are put on waiting list for organ transplantation and over 6,000 of them die due to shortage or inability to get the suitable donor. This represents a huge opportunity for the players active in the global 3D bioprinting market to incentivize this revenue opportunity by engineering organ at scale to meet the demand and supply gap.

In fact, bioprinting is an emerging technology that enables the printing of nearly any type of biological tissue and organ. This technology has already been used to create structures such as heart valves, skin patches, and bone implants. However, there are still many applications for bioprinting that have yet to be explored.

3D printing is revolutionizing the way products are designed, and it is now being used to create organs at scale. By printing organs in a customized manner, we can improve the accuracy, predictability, and efficiency of organ printing.

There are many different types of organs that could benefit from bioprinting. Examples of organs that could be printed using this technology include lungs, liver, kidneys, and hearts. With bioprinting, surgeons could potentially print new organs onsite if they become damaged or diseased.

The applications for 3D bioprinting market are endless, and we are just starting to scratch the surface of what this technology can do. We believe that bioprinting will play a major role in engineering organ at scale in the future.

Download Full Report (176 Pages PDF with Insights, Charts, Tables, Figures) at@ https://www.vantagemarketresearch.com/industry-report/3d-bioprinting-market-1235

As per Vantage Market Research, end-users and scientist have started paying attention to making use of 3D bioprinting on large scale thanks to numerous benefits of using 3D bioprinting for organ engineering. Some of the most important benefits include:

Browse market data Tables and Figures spread through 176 Pages and in-depth TOC on "3d Bioprinting Market by Technology (Inkjet-based, Magnetic Levitation, Syringe-based, Laser-based), by Application (Medical, Dental, Biosensors, Consumer/Personal Product Testing), by Region (North America, Latin America, Europe, Asia Pacific) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Inkjet Technology Generates More than 38% Revenue of Bioprinting Market

3D bioprinting market is becoming popular due to its versatility and ability to create complex tissue structures. However, one disadvantage of 3D bioprinting is the need for magnetic levitation technology in order to print large objects. Inkjet technology is becoming more popular for 3D bioprinting due to its lower printing costs and the ability to print larger objects. Inject technology uses a syringe filled with liquid bioprinters to create realistic tissue constructs.

Some of the biggest advantages of inkjet technology in the global 3D bioprinting market include its low cost and the ability to print complex tissue constructs. Inkjet printers can also produce large quantities of tissue at once, which makes them ideal for medical applications. Deploying inject printers in hospitals could improve the quality of patient care by allowing for faster production of customized tissue constructs. In addition, inject printers could help to reduce the cost of healthcare by reducing the need for magnetic levitation technology.

As per Vantage Market Research, most of the users in the global 3D bioprinting market prefer inkjet bioprinting technology because the printing can be faster and more accurate than magnetic levitation printing. Second, inkjet printing does not require the use of a cold bed or vacuum chamber both of which can be time-consuming and expensive to set up. Third, inkjet printing is less likely to produce errors due to materials incompatibility than magnetic levitation printing. Inkjet printing is also better at reproducing delicate features and patterns than magnetic levitation printing.

Overall, inkjet technology is becoming more popular for 3D bioprinting due to its speed, accuracy, and versatility.

Key Questions Answered in The Report:

Customization of the Report:

The report can be customized as per client needs or requirements. For any queries, you can contact us on sales@vantagemarketresearch.com or +1 (202) 380-9727. Our sales executives will be happy to understand your needs and provide you with the most suitable reports.

Browse More Related Report:

About Vantage Market Research:

We, at Vantage Market Research, provide quantified B2B high quality research on more than 20,000 emerging markets, in turn, helping our clients map out constellation of opportunities for their businesses. We, as a competitive intelligence market research and consulting firm provide end to end solutions to our client enterprises to meet their crucial business objectives. Our clientele base spans across 70% of Global Fortune 500 companies. The company provides high quality data and market research reports. The company serves various enterprises and clients in a wide variety of industries. The company offers detailed reports on multiple industries including Chemical Materials and Energy, Food and Beverages, Healthcare Technology, etc. The companys experienced team of Analysts, Researchers, and Consultants use proprietary data sources and numerous statistical tools and techniques to gather and analyse information.

Follow Us on LinkedIn: https://www.linkedin.com/company/vantage-market-research/

Follow Us on Twitter: https://twitter.com/vantagemarketr

Follow Us on Facebook: https://www.facebook.com/vantagemarketresearch

Contact us

Eric Kunz

6218 Georgia Avenue NW Ste 1 - 564

Washington DC 20011-5125

United States Tel: +1 202 380 9727

Email: sales@vantagemarketresearch.com

Website: https://www.vantagemarketresearch.com/

Latest Vantage Market Research Press Releases @https://www.vantagemarketresearch.com/insight/press-releases

Latest Vantage Market Research Blog @ https://www.vantagemarketresearch.com/insight/blogs

Blog:

See more here:
3D Bioprinting Market Size to Touch Valuation of $1.5 Billion by 2028 | Inkjet Technology Generates More than 38% Revenue of Bioprinting Market -...

COLUMBIA, MO - (NewMediaWire) - October 3, 2022 - via QC Kinetix - QC Kinetix (Columbia) therapies work by stimulating the body's natural healing abilities to heal damaged tissues much faster than normal.

Although unpleasant, pain is many times useful to our bodies as it signals us about body parts that need more attention and care. However, some pain can persist for several weeks, months, or even years and negatively affect the quality of life. In many cases, physicians recommend surgery or prescription medication when other interventions have failed. These recommendations often come unwelcome by patients. Fortunately, technology and innovation have led to the discovery of new, effective ways of treating pain naturally, such as through regenerative medicine.

QC Kinetix (Columbia) treats different types of mild and severe pain naturally using regenerative medicine. The clinic has a wide spectrum of treatments that do not involve surgery or prescription of addictive medications. The therapies work by stimulating the body's natural healing abilities to heal damaged tissues much faster than normal, resulting in pain relief and reduced inflammation. They treat many conditions, including pain in the knee, back, wrist, shoulder, ankle, hip, and other body parts. They also treat pain in the large joints like the legs and small joints like fingers and toes caused by degenerative conditions like arthritis.

The pain control clinic offers customized treatment plans that are tailor-made to meet patients' unique health needs. They begin each treatment with a free consultation that diagnoses patients' conditions and informs on patients' eligibility for regenerative medicine. The consultation involves a thorough analysis of the patient's medical history and may require additional tests to improve accuracy in diagnosis. This is followed by a recommendation of the most useful therapies based on the diagnosis. The physician takes time to explain to patients what regenerative medicine entails and how it can help them to improve their condition.

QC Kinetix (Columbia)'s treatments help relieve many symptoms, including limited joint mobility, swelling, redness, stiffness, bone-on-bone grinding, knee cracking, popping, and many more. The procedures allow patients to get back to their normal lives fast, as they barely have any downtime once the healing process begins. They are minimally invasive, have long-lasting results, and improve function and quality of life. The clinic offers a personalized concierge-level service that provides logistical support to patients receiving treatment at the facility. The physicians keep patients informed every step of the process.

The pain control clinic has an entire division dedicated to providing regenerative medicine for sports and accident injuries. The therapies are ideal for when patients have tried the common advice of rest, ice, compression, and elevation but have failed in rehabilitating the injuries. The clinic steps in to offer a full recovery regime that combines traditional sports injury treatments, rest, and bracing with regenerative medicine for the best possible results. The therapies do not only heal the injured areas but also strengthen the tendons, ligaments, and cartilage to avoid re-injury. Some of the sports injuries they treat include golfer's elbow, torn Meniscus, torn rotator cuff, torn ACL/MCL, and joint and musculoskeletal pain from a thrown-out joint or muscle.

QC Kinetix (Columbia) has invested in advanced technologies and modern equipment that improves paint outcomes. Regenerative medicine remains one of the fastest growing industries, which has led them to adopt a continuous learning culture that allows easy adoption of new, well-researched techniques that match industry trends. Treatments are administered by a team of board-certified physicians with extensive experience in the industry. They use a patient-centered approach that focuses on meeting patient needs and encouraging patient engagement.

The clinic representative had this to say about their services,

"When you visit our facility in Columbia, MO, an orthopedic specialist from our Team Will evaluate you and review your symptoms and previous treatments. QC Kinetix (Columbia) has several regenerative protocols that we use to create customized treatment plans for every patient. Our natural pain treatments can address joint pain and produce long-lasting results."

QC Kinetix (Columbia) is located at 3700 I-70 Dr. SE, Suite 106, Columbia, MO, 65201, US. For consultation and booking, contact their staff by calling (573) 545-5588. Visit the company website to learn more about their Columbia office and their non-surgical regenerative medicine treatments for mild and severe pains and injuries.

Media Contact:

Company Name: QC Kinetix (Columbia)

Contact Person: Scott Hoots

Phone: (573) 545-5588

Address: 3700 I-70 Dr SE, Suite 106

City: Columbia

State: MO

Postal Code: 65201

Country: US

Website: https://qckinetix.com/mid-missouri/

Original post:
QC Kinetix (Columbia) Offers Regenerative Medicine Treatments to Treat Different Types of Physical Pain and Injuries - Yahoo Finance

TOKYOand HENNIGSDORF, Germany, Oct. 3, 2022 /PRNewswire/ --Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pantherna Therapeutics GmbH (CEO:Klaus Giese, Ph.D., "Pantherna") today announced that the companies have entered into a new technology evaluation agreement for research to generate mRNA-based regenerative medicine programsusing direct reprogramming (transdifferentiation)*.

This agreement expands the scope of the technology evaluation agreement for research, which Astellas and Pantherna entered into in 2021, to include new target organ.

Pantherna owns a proprietary platform of state-of-the-art, unique mRNA molecules (PTXmRNAs) for enhancing the efficiency of mRNA actions in the body. Under the new agreement, Pantherna's mRNA platform and Astellas' world-class drug discovery capabilities will be combined to promote research on the generation of regenerative medicine programsfor new target organ using a direct reprogrammingapproach. Astellas will be responsible for providing drug discovery ideas, preparing candidate compounds for technology evaluation, and performing research aimed at developing this therapeutic modality, while Pantherna will be responsible for providing technical information and development support.

"We are excited about this expansion of our collaboration with Astellas," said Pantherna's Chief Executive Officer, Klaus Giese, Ph.D. "We feel honored that Astellas, as a leading pharmaceutical company, has underscored their interest in leveraging the unique aspects of our proprietary therapeutic mRNA technology."

"Through this agreement, which expands the scope of our collaboration with Pantherna, we will create innovative regenerative medicine programs for new target organ, and we expect that we will be able to thereby expand the treatment options for diseases with high unmet medical needs." said Taiji Sawamoto, Ph.D.,Executive Vice President, Applied Research & Operations, at Astellas. "The collaboration with Pantherna is an initiative which synergistically integrates Astellas' expertise with mRNA as a therapeutic modality and its capabilities cultivated in the research field of directreprogramming,and will promote the development of next-generation treatments using a new modality/technology based on the Focus Area approach strategy."

* Direct reprogramming: Direct conversion of the fate of cells without passing through the pluripotent state. https://www.astellas.com/en/science/direct-reprogramming-research-unit

About AstellasAstellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+ healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.

About PanthernaPantherna Therapeutics is a privately held biopharmaceutical company developing first-in-class therapeuticsfor vascular diseases.Pantherna's innovative technology platform is based on advanced lipid nanoparticles for thetarget-specific, selective delivery and expression of therapeutic mRNA drugs in organs and tissues such as the endothelium. Pantherna Therapeutics was recently awarded with a 2022 Pharma Trend Honor for its lead candidate PAN004 in the category "Most Innovative Product: Leap Innovations-NucleicAcid-BasedDrug Development"

(https://businesswire.com/news/home/20220916005215/en/Pharma-Trend-Honors-the-Best-Pharmaceutical-Companies-and-the-Most-Innovative-Products_2022). Pantherna is based in Hennigsdorf,Brandenburg (Innovationsforum) close to Berlin, Germany. For more information, please visit our website at https://pantherna-therapeutics.com/.

Cautionary Notes(Astellas)In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas'intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

SOURCE Astellas Pharma Inc.

See the original post:
Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative...

Throughout the life of a woman, her body changes, and so does the intimate sphere. It can be subject to pregnancy, childbirth, menopause, hormonal changes, cancer problems and natural aging. All this causes internal and external changes to occur in the vaginal area, which can affect its appearance and the sensations it experiences.

Vaginal rejuvenation may be the solution to these problems, representing a breakthrough in regenerative medicine and gynecology. It is possible to restore or restore the normal functioning of female organs through various procedures.

Dr. Maria Jose Gomez, a specialist in regenerative and aesthetic gynecology, specializes in and provides innovative vaginal rejuvenation treatments to her patients. It aims to provide minimally invasive solutions and achieve progressive results by excluding the need to undergo a surgical procedure.

Who is Vaginal Rejuvenation for?

Rejuvenation refers to a set of non-surgical techniques that seeks to treat problems in the vagina. The purpose of applying these procedures is to cure problems such as urinary incontinence, vulvar lichen sclerosus, vaginal dryness, itching or atrophy of the region.

They are also used to prevent low elasticity, pain in intimate relationships, loss of tone in the walls of the vagina, genital prolapse and relaxation of the pelvic floor. Other problems in which vaginal rejuvenation is indicated are episiotomy scars that have worsened and diminished over the years.

These treatments represent a great advance, as they allow solving problems that until a few years ago were only treated with surgery in the most severe cases. For milch people, they were neither considered nor noticed, as they were thought to be a normal effect of age.

Methods by Dr. Maria Jose Gomezu

One of the methods used by Dr. Maria Jose Gomez for vaginal rejuvenation is the CO2 laser. With this state-of-the-art, non-invasive device, it achieves excellent results for the treatment of menopausal, postpartum, urinary incontinence and undesirable effects of vulvar sclerotrophic lichen.

It also applies hyaluronic acid treatment combined with platelet-rich plasma to hydrate or volumize the labia majora, improving the aesthetics of the area. But, in addition, it helps to reproduce and improves the functionality of the female genitalia, curing malformations such as atrophy and vaginal dryness.

Laser labiaplasty is one of his procedures used for vaginal rejuvenation. Through this, excess tissue of the labia minora is removed when they are enlarged, using a CO2 laser, providing faster recovery and immediate results. Its purpose is to give a harmonious look to the vulva and to treat the discomfort presented in the area.

At its centers located in Madrid and Alicante, Dr. Mara Jos Gmez Fernndez offers her patients a completely free first consultation to offer her patients the best treatment tailored to their needs.

Continued here:
Company / An Advance In Vaginal Rejuvenation, Regenerative Medicine And Aesthetic Gynecology - World Nation News

Teijin Limited,Japan Tissue Engineering Co., Ltd.(J-TEC),Mitsui Fudosan Co., Ltd.and theNational Cancer Center(NCC)jointly announced today thatthey willestablish a regenerative medicine platform inKashiwanoha Smart City,a life sciencebusiness park in Kashiwa-shi, Chiba Prefecture, Japan. The platform supports the development of innovative treatments for diseases with unmet needs such as cancer. It serves a one-stop system supporting research and development, business plan formulation, and commercial production of regenerative medicine products.In particular, the four partners aim to accelerate the commercialization of regenerative medicine and innovative treatments for cancer.As part of the plan, the partners already have begun to support seed holders.

Looking at the four partners: NCC provides cutting-edge cancer treatments and produces drug discovery seeds; J-TEC has extensive experience in product development, manufacturing and marketing as a pioneer of regenerative medicines; Teijin boasts expertise in drug research, development and marketing; and Mitsui Fudosan builds spaces and communities for innovation in life sciences. Their envisioned platform, taking advantage of the physical and functional proximity of the four parties, is expected to quickly and efficiently provide solutions for manufacturing and clinical development, business planning and commercial production. The contract development and manufacturing organization (CDMO) served by Teijin and J-TEC will be located in Mitsui Link-Lab Kashiwanoha 1 operated by Mitsui Fudosan, and is adjacent to the NCC Hospital East and NCC Exploratory Oncology Research & Clinical Trial Center.

The platform will also support projects of other organizations that have seeds. NCC will provide professional consulting and collaboration with seeds holders and investigator-initiated clinical trials. Teijin and J-TEC offer practical consulting and support for contracted development and manufacturing. Mitsui Fudosan will be responsible for venue operation and providing support for individual initiatives.

In preparation to start up the CDMO facility scheduled to open in January 2024, the platform will promote the development of regenerative medicines among academic institutions,start-up companies, pharmaceutical companies and others. It also will solicit research and development and clinical collaborations with medical institutions as well as key opinion leaders (KOL) and business enterprises in the fields of cancer and regenerative medicine.

With this agreement, the four parties will strive to stimulate demand and build up their platform, aiming eventually at establishing a structure capable of supporting about 10 projects annually with the purpose of bringing regenerative medicines to market. Teijin, in collaboration with J-TEC, will invest a substantial portion of its more than JPY 3 billion CDMO-related investment budget into the project, mainly for facilities and human resource training in Mitsui Link-Lab Kashiwanoha 1 over the next two to three years, thereby helping to establish a CDMO facility mainly for supporting the development of manufacturing methods as well as actual manufacturing. Ultimately, the four parties expect to contribute to global medical care by providing new options for patients waiting for innovative treatments.

According to the NCC, some one million people are diagnosed with cancer each year in Japan. Development of innovative treatments using regenerative medicines, including genetically modified immune cell therapy, also known as chimeric antigen receptor (CAR-T) cell therapy, has been ongoing worldwide in recent years. In addition, research and development of promising treatments and their seeds are under way. Meanwhile, the practical application of regenerative medicine requires specialized knowledge and practical experience regarding matters such as pharmaceutical approval and quality control. A wide range of commercialization knowhow also is required. As a result, many academic institutions and start-up companies are unable to commercialize their research and development independently. Teijin, J-TEC, Mitsui Fudosan and NCC, based on their clear understanding of such needs, have now agreed to establish a regenerative medicine platform to provide academic institutions with professional expertise and commercialization knowhow on a collaborative basis.

Kashiwa-no-ha Smart City, which is served by Kashiwa-no-ha Campus Station about 30 minutes by express train from central Tokyo, is an area with accumulation of Japans leading academic and medical institutions for some of Japan's leading academia and medical facilities. In addition to Mitsui Garden Hotel Kashiwa-no-ha Parkside, which supports cancer patients, the smart city has become a lively community of offices and commercial facilities.Mitsui Link Lab Kashiwanoha 1, located at6-6-2 Kashiwanoha, Kashiwa-shi, ChibaPrefecture, comprises about11,000m2of total floor space and offers rentalspace ofabout 8,000 m2.

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan's first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon fibers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement Human Chemistry, Human Solutions, Teijin aims to be a company that supports the society of the future. The group comprises some 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY 926.1 billion (USD 7.2 billion) and total assets of JPY 1,207.6 billion (USD 9.4 billion) in the fiscal year that ended on March 31, 2022.

Please visitwww.teijin.com

About J-TEC

J-TEC (TSE: 7774) is a maker of regenerative medical products whose corporate vision is creating a future for regenerative medicine, and has been a member of the Teijin Group since March 2021. As Japans top runner in regenerative medicine, J-TEC obtained marketing approval for autologous cultured epidermis JACE, Japans first regenerative medical product, in October of 2007, and began marketing the product in January of 2009. J-TEC then went on to obtain marketing approval for Autologous Cultured Cartilage JACC in July of 2012, for Autologous Cultured Corneal Epithelium Nepic in March of 2020, and for Autologous Cultured Oral Mucosal Epithelium Ocural in June 2021. Of the 16 regenerative medical products that have been approved in Japan, four are J-TEC products. By making the most of the experience and knowhow cultivated through these achievements, J-TEC is engaging in contract development of regenerative medical products, consulting, and contract manufacture of specific cell-processed products.

Please visitwww.jpte.co.jp/en/

About Mitsui Fudosan Co., Ltd.

(Kashiwa-no-ha Smart City:https://www.kashiwanoha-smartcity.com/en/)

Mitsui Fudosan is a comprehensive developer that creates new value by striving to resolve social issues through urban development. At Kashiwa-no-ha Smart City, Mitsui Fudosan aims to create a smart, compact city driven by data through the introduction of new technologies such as AI and IoT. It has been selected by the Ministry of Land, Infrastructure, Transport and Tourism as an advanced model project for a smart city towards realizing Society 5.0. Going forward, Mitsui Fudosan will work on developing smart medical institution services for health and medicine. In addition, the Mitsui Fudosan Group believes that it can contribute significantly to the realization of Society 5.0, which is advocated by the Japanese government, and to the achievement of the SDGs, by promoting ESG management, which means advancing businesses based on an awareness of the Environment (E), Society (S), and Governance (G).

About National Cancer Center Japan

The National Cancer Center Japan, established in 1962, is a leading medical institution in cancer treatment and research in Japan. It is actively involved in physician-led clinical trials and clinical research, and has produced a wealth of research results that have led to the development of new drugs.

Press ContactCorporate CommunicationsTeijin Limited+81 (0)3 3506 4055pr@teijin.co.jp

Corporate Communication OfficeJapan Tissue Engineering Co., Ltd.+81 (0) 533 66 2020jtec-info@jpte.co.jp

Public Relations DepartmentMitsui Fudosan Co., Ltd.+81 (0)3 32463155

Office of Public Relations, Strategic Planning BureauNational Cancer Centerncc-admin@ncc.go.jp

More:
Teijin, J-TEC, Mitsui Fudosan, and NCC to create a new platform for regenerative medicine innovation - The Worldfolio

Dr. Joseph Mejia, DO, FAAPRM&R, RMSK has been selected as a Castle Connolly Top Doctor in the field of orthopedic and regenerative medicine. Triple board certified in Physical Medicine and Rehabilitation, Interventional Pain Management and Sports Medicine, Dr. Mejia offers vast experience and expertise in nonsurgical orthopedic medicine.

Dr. Mejia serves as the medical director at Performance Rehabilitation & Regenerative Medicine in Somerset County alongside Dr. Ronald Spiaggia, the founding partner of the practice. In addition to receiving extensive training in Regenerative Medicine, Dr. Mejia is fellowship-trained in Interventional Pain/Musculoskeletal Medicine and is licensed in both New Jersey and New York. He also is certified in diagnostic musculoskeletal ultrasound and has received comprehensive training in Regenerative Medicine for advanced spine conditions. Dr. Mejia is known as a pioneer in Regenerative Medicine, having been published in multiple projects and publications, and conducting highly sought-after courses and workshops.

Dr. Mejia completed his undergraduate degree at the University of Michigan, Ann Arbor, where he received a Bachelor of Science degree in biology. He then earned a medical degree at the West Virginia School of Osteopathic Medicine. After completing his residency at New York University/Rusk Institute of Rehabilitation, he received fellowship training in Interventional Pain/Musculoskeletal Medicine at UMDNJ/Kessler Institute for Rehabilitation. He currently resides in Wayne, N.J., with his wife and four children. He is a dedicated family man with interests in traveling, photography, computers and playing basketball.

As founding partners ofPerformance Rehabilitation & Regenerative Medicine, Dr. Mejia and Dr. Spiaggia have pioneered new approaches to orthopedic treatments, sports injuries, acute and chronic spine-related disorders, herniated discs, radiculopathy, spinal cord injuries, acute and chronic joint injuries, osteoarthritis, rotator cuff tears, meniscus tears, tendinopathies, ligament tears and nerve entrapments.

AtPerformance Rehabilitation & Regenerative Medicinewe strive to get to the root cause of peoples spine and joint pain, Dr. Mejia said. Our clinic uses a proven, team-based approach that gets results. Our state-of-the-art facilities allow patients to consult with medical physicians, physical therapists, occupational therapists, acupuncturists, neurosurgeons, and orthopedic surgeons, all under one roof.

Performance Rehabilitation & Regenerative Medicine maintains offices in Watchung, Branchburg and Somerset to reach patients across New Jersey. Dr. Mejia and the Performance Rehabilitation & Regenerative Medicine team recently opened a new surgery and pain management center in Bridgewater.

I strive to reduce or eliminate pain for my patients and return them to their prior level of function so they can get back to doing what they love, Dr. Mejia commented. I utilize the latest imaging technology to diagnose and guide specific treatments for their condition with the highest level of precision. I listen to my patients and collaborate with other health care professionals, when necessary, to work toward a common goal of improving quality of life.

Performance Rehabilitation and Medicine has served more the 30,000 patients over the past 21 years. To learn more about Dr. Mejia andPerformance Rehabilitation & Regenerative Medicine or to book and appointment visitperformancerehabnj.comor call 908-754-1960.

Office Locations

Performance Rehabilitation & Regenerative Medicine of Branchburg

3150 Route 22, Branchburg, NJ 08876

Performance Rehabilitation & Regenerative Medicine of Somerset

454 Elizabeth Ave., Suite 240, Somerset, NJ 08873

Performance Rehabilitation & Regenerative Medicine of Watchung

459 Watchung Ave., Watchung, NJ 07069

Performance Surgical Associates (Surgery Center)

1081 Route 22, Bridgewater, NJ 08807

Hospital Affiliations

RWJ University Hospital Rahway

Hackensack Meridian Mountainside Medical Center

Hudson Regional Hospital

Carepoint Health-Bayonne Medical Center

The Valley Hospital

Expertise

Pain Management and Orthopedics

Physical Therapy

Occupational Therapy

Regenerative Medicine

Specialties

Non-Surgical Treatments, Physical Medicine and Rehabilitation, Interventional Pain Management, Sports Medicine,Regenerative Medicine, Stem Cell Therapy, PRP,Radiofrequency Ablation (RFA)Therapy, Ultrasound Guided Injections, Diagnostic Musculoskeletal, Nerve Conduction Studies and Electromyography, Acute and Chronic Spine Related Disorders,Herniated Discs,Spinal Stenosis,Spinal Cord Injuries,Spinal Cord Stimulation, Acute and Chronic Joint Injuries,Osteoarthritis, Rotator Cuff Tears, Meniscus Tears,Tendinopathies, Ligament Tears,Nerve Entrapments, Orthopedic Surgery, Arthroscopic Surgery, Neuro Surgery, Physical Therapy, Occupational Therapy.

Board Certification

American Board of Physical Medicine & Rehabilitation

American Board of Pain Medicine

American Board of Sports Medicine

Affiliations

American Academy of Physical Medicine & Rehabilitation

Association of Academic Physiatrists

New York Society of Physical Medicine & Rehabilitation

American Society Interventional Pain Physicians

International Spine Intervention Society

American Medical Association

American Osteopathic Association

View post:
Performance Rehabilitation and Regenerative Medicine's Dr. Joseph Mejia honored as a Castle Connolly Top Doctor - Jersey's Best

Cell Regeneration Medicine Market Snapshot (2022-2032)

[250 Pages Report] According to Future Market Insights newly releasedCell Regeneration Medicine Marketanalysis report, the global market valuation stands atUS$ 30.3 Bnin 2021 and is expected to be valued atUS$ 34.3 Bnby the end of 2022. The market is expected to rise significantly at a CAGR of14.4%and the global valuation is expected to beUS$ 130.8 Bnby the end of 2032. During the forecasted period (2022-2032), the global market is anticipated to offer an absolute dollar opportunity ofUS$ 96.5 Bn.

The Therapeutics segment is predicted to be the top product segment in the Cell Regeneration Medicine Market with an expected CAGR of16.5%for the period between 2022 and 2032. This is significantly higher from the historical CAGR of14.1%owing to higher adoption of primary cell-based therapies in clinical application and their increased usage in different therapeutic indications.

Furthermore, Cell Regeneration Medicine garners highest revenue through the Oncology segment, which accounts for over a quarter share. The market revenue through Oncology segment is expected to experience the CAGR of13.1%in the therapeutic category as compared to its historical average of11.4%.The category is expected to rise due to high cancer prevalence, increasing investments in cancer research, development of advanced cell therapies and initiatives to reduce cancer burden.

Revenue of Cell Regeneration Medicine Market from 2017 to 2021 Compared to Demand Outlook for 2022 to 2032

As per the publications released by Future Market Insights market research and competitive intelligence provider, on Cell Regeneration Medicine Market, the market is currently valued atUS$ 30.3 Bnin 2021 and is expected to rise at a CAGR of14.4%during the period between 2022 and 2032. This growth has been significantly higher than the historical growth of12.4%.The market is expected to offer an absolute dollar opportunity ofUS$ 96.5 Bnbetween 2022 and 2032. By the end of 2032, the global market for Cell Regeneration Medicine is likely to hit the valuation ofUS$ 130.8 Bn.

Request a Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15084

The market valuation is projected to grow at a significant CAGR of14.4%as compared to historical CAGR of12.4%owing to factors such as introduction of gene therapy, advancements in stem cell and tissue engineering, ongoing funding in R&D by government and commercial entities and continuous regulatory approvals for advanced therapeutic medical products.

What Factors are driving the Growth of Cell Regeneration Medicine Market?

Global Cell Regeneration Medicine Market is likely to be driven by theintroduction of gene therapy,advancements in stems cells and growth intissue engineering. Furthermore, various projects like T-Cell therapy, which comes underthe manufacturing industry of cell therapyregenerative medicinearebeing undertaken by any businesses in cooperationwith other businesses or research institutions. Furthermore, the government regulatory approvals has led to increase in the market growth.

The global pandemic has provided the global players with various chances to bring medicinal solution to fight against SARS-COV-2. Along withvarious initiatives, theongoing investments bygovernment and private sector agencies inR&D has accelerated the industrys advancement. Companies are collaboratingto expand their R&D skills to develop and sell innovative therapies to secure a position in a competitive global market.

Researchers perspectives on Cell Regeneration Medicine have been transformed by technological developments like Nanotechnology,3D bioprintingtechniques and AIin stem cell-based therapeutics. These developments aremakingdermatological grafting operations like persistent burns, bone abnormalities and skin woundsmore efficient. The market is being driven by the rising frequency of chronic medical conditions and genetic abnormalities such as congestive heart failure, myocardial infarction, Parkinsons disease andvarious kinds of bone losses. In addition, the growing elderly populationsuffering from musculoskeletal, oncologicaland cardiological problemsis driving market expansion.

ContactourMarket Research Specialist @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-15084

What Factors are restraining the Growth of Global Cell Regeneration Medicine Market?

The sales of Cell Regeneration Medicine is likely to be affected by the high cost of therapies. This high cost of treatment acts as a barrier in entering the new market. People in emerging economies are unable to finance organ transplantation due to socioeconomic constraints. Organ trafficking is a serious crime that is inprevalencedue to a scarcity of organs.

The developing countries pose to be a potential marketwith rising rates of chronic diseases, hereditary diseases, rising geriatricpopulation and higher demanding regionsfor organs and biomaterials. Butwithlittle awareness of Cell Regeneration Medicine, these potential markets are difficult to capture. The gene correction treatment involves nucleases that have been modified to successfully change the human genome. However, the use of gene correction treatment is limited due to someunintended consequences, such as cell manipulation, which hasimpacted the efficacyofcell formation and proliferation. However, with sufficient capital and financing, R&D is proceeding toward the cost-effective commercialization of such complex medical operations.

Country-wise Analysis

Which Country is the Driving Force for the growth of the Global Cell Regeneration Medicines Market?

In 2021, the United States Accounted for nearly 2/5th share of the global market for Cell Regeneration Medicines. The U.S. market growth is significantly higher from its historical average growth of11.9%. Between 2022 and 2032, the market is estimated to witness an absolute dollar opportunity ofUS$ 36.6 Bn.

The presence of significant playersin the United States, the availability of modern technologiesand increasing financing ofresearch institutes involved in the creation of innovative treatments can all be attributed to this expansion. In addition, the United States has the biggest revenue flow due to a large number of clinical trials, the availability of financing, and various government and private-sector efforts. For example, the US Department of Health and Human Services launched a campaign to place Cell Regeneration Medicine at the forefront of healthcare.

Which Country is expected to grow rapidly in the Global Cell Regeneration Medicines Market?

According to Future Market Insights data, the market in China is anticipated to growat the fastest rate of18.2%between 2022 and 2032. Theprojected CAGR of the U.S. is significantly higher than the historical CAGR of13.7%. In the next ten years, the Chinese market is estimated to offer an absolute dollar opportunityofUS$ 14.8 Bnto reach a valuation ofUS$ 17.8 Bn.

The rising CAGR of the Chinese market for Cell Regeneration Medicines is attributed to the rapid expansion of healthcare infrastructure and research institutes to accelerate stem cell research in a rapidly developing market. With rising government approvals forresearch projects involving human embryonic stem cells,scientists are encouragedto investigate the cellsclinical potential. Additionally, the rising prevalence of cardiovascular and musculoskeletal illnesses is driving this trend. Furthermore, the market is likely to be explored by global players targeting the untapped segments of the market.

Category-wise Insights

Which Product Type is gaining the Utmost Traction in Cell Regeneration Medicine Market?

The Therapeutics segment is the largest revenue generating segment in the Global Cell Regeneration Medicine Market, growing at a CAGR of17.8%during the period between 2022 and 2032.

Despite source diversification, this category is anticipated to maintain its leadership position in the marketplace throughout the projected period. Primary cell-based therapies are the most developed medications available from the medical sector, as they are suitable for use in both clinical applications and approved in different areas. In addition, the stem cell & progenitor cell-based therapies market is predicted to grow significantly over the forecast years, owing to increased investments in stem cell research and regulatory policy revisions.

Which Therapeutic Category is expected to drive the Growth of Global Cell Regeneration Medicines Market?

Oncology therapeutic category is expected to lead the market with the highest share in global market for Cell Regeneration Medicines. It is forecasted to grow at a CAGR of13.1%during the period.

This can be attributable to high cancer prevalence globally and the development of efficient cancer treatment options. Furthermore, huge investments by government organizations and private companies to finance cancer research is aiding the growth.

Competitive Analysis

A number of companies invested in the development of cell regenerative medicine to meet demand for clinical needs without resorting to more-invasive procedures. The market is extremely competitive, and players are making joint efforts for product development.

Some of the prominent Cell Regeneration Medicine manufacturers are AstraZeneca plc, Astellas Pharma, Inc., F. Hoffmann-La Roche Ltd., Integra Lifesciences Corp., Cook Biotech, Inc., Bayer AG, Pfizer, Inc., Merck KGaA, Abbott, Vericel Corp., Novartis AG, GlaxoSmithKline (GSK), Baxter International, Inc., Takara Bio, Inc.

Get in Touch With Our Team For 20% Flat Discount @ https://www.futuremarketinsights.com/request-discount/rep-gb-15084

The recent developments in the Global Cell Regeneration Medicine Market are:

Cell Regeneration Medicine Market Report Scope

Details

Forecast Period

2022-2032

Historical Data

2017-2021

Quantitative Units

In US$ Mn

Key Regions Covered

North America, Latin America, Europe, APAC and MEA

Key Countries Covered

United States, China, Japan, South Korea, U.K., Canada, Brazil, Mexico, Germany, France, Spain, Italy, Russia, India, Australia, South Africa, Saudi Arabia, UAE, Israel

Key Market Segments Covered

Product Type, Therapeutic Category and Region

Market Segments Covered in Cell Regeneration Medicine Market Analysis

By Product Type:

By Therapeutic Category:

By Region:

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:Future Market Insights,Unit No: 1602-006,Jumeirah Bay 2,Plot No: JLT-PH2-X2A,Jumeirah Lakes Towers,Dubai,United Arab EmiratesFor Sales Enquiries:sales@futuremarketinsights.comWebsite:https://www.futuremarketinsights.comLinkedIn|Twitter|Blogs

View original post here:
Cell Regeneration Medicine Market to be valued at US$ 34.3 Bn by the end of 2022 | FMI Research - PharmiWeb.com